In particular, the anti-PD-1 subgroup exhibited a higher incidence of hyperthyroidism and renal disorders, whereas anti-PD-L1 therapy was associated with an increased risk of IRRs (Fig. S7). This evidence concerns the gene CD274 and hyperthyroidism.